Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease

Alex I. Malinin, Dan Atar, Kevin P. Callahan, Marcus E. McKenzie, Victor L. Serebruany

Research output: Contribution to journalArticle

Abstract

We sought to assess how one tablet of non-enteric coated aspirin (325 mg) affects human platelets in subjects with risk factors for coronary artery disease. Data from 63 individuals with multiple cardiac risk factors were analyzed. Platelets were assessed twice at baseline (pre-aspirin), and after 3-4 h (post-aspirin). We employed 5 μM epinephrine-induced conventional aggregometry, closure time with epinephrine/collagen cartridge by PFA-100® (Dade-Behring), and aspirin response units (ARU) stimulated by propyl gallat with Ultegra® (Accumetrics, San Diego, CA, USA) for measuring platelet function. In addition, the expression of platelet receptors was determined by using the following monoclonal antibodies: anti-CD31, CD41, CD42b, CD51/CD61, CD62p, CD63, CD107a, and CD151. Platelet-leukocyte formation was detected utilizing dual antibodies for a pan-platelet marker CD151, and CD14, a monocyte/macrophage marker. PAC-1 was used to measure fibrinogen-platelet binding. One pill of aspirin significantly decreased platelet-rich plasma (PRP) aggregation (74.18±16.75% vs. 24.92±8.64%; p2=0.73-0.86) between platelet analyzer readings and aggregation was observed. One tablet of aspirin moderately inhibited expression of most surface platelet receptors measured, and such inhibition reached significance (p

Original languageEnglish (US)
Pages (from-to)139-143
Number of pages5
JournalEuropean Journal of Pharmacology
Volume462
Issue number1-3
DOIs
StatePublished - Feb 21 2003

Fingerprint

Aspirin
Coronary Artery Disease
Blood Platelets
Epinephrine
Enteric-Coated Tablets
Platelet-Rich Plasma
Fibrinogen
Tablets
Reading
Monocytes
Leukocytes
Collagen
Macrophages
Monoclonal Antibodies
Antibodies

Keywords

  • Aspirin
  • Coronary artery disease
  • Platelet
  • Receptor

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. / Malinin, Alex I.; Atar, Dan; Callahan, Kevin P.; McKenzie, Marcus E.; Serebruany, Victor L.

In: European Journal of Pharmacology, Vol. 462, No. 1-3, 21.02.2003, p. 139-143.

Research output: Contribution to journalArticle

Malinin, Alex I. ; Atar, Dan ; Callahan, Kevin P. ; McKenzie, Marcus E. ; Serebruany, Victor L. / Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. In: European Journal of Pharmacology. 2003 ; Vol. 462, No. 1-3. pp. 139-143.
@article{fdb06d88d7554e8d9424133cdc1cc340,
title = "Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease",
abstract = "We sought to assess how one tablet of non-enteric coated aspirin (325 mg) affects human platelets in subjects with risk factors for coronary artery disease. Data from 63 individuals with multiple cardiac risk factors were analyzed. Platelets were assessed twice at baseline (pre-aspirin), and after 3-4 h (post-aspirin). We employed 5 μM epinephrine-induced conventional aggregometry, closure time with epinephrine/collagen cartridge by PFA-100{\circledR} (Dade-Behring), and aspirin response units (ARU) stimulated by propyl gallat with Ultegra{\circledR} (Accumetrics, San Diego, CA, USA) for measuring platelet function. In addition, the expression of platelet receptors was determined by using the following monoclonal antibodies: anti-CD31, CD41, CD42b, CD51/CD61, CD62p, CD63, CD107a, and CD151. Platelet-leukocyte formation was detected utilizing dual antibodies for a pan-platelet marker CD151, and CD14, a monocyte/macrophage marker. PAC-1 was used to measure fibrinogen-platelet binding. One pill of aspirin significantly decreased platelet-rich plasma (PRP) aggregation (74.18±16.75{\%} vs. 24.92±8.64{\%}; p2=0.73-0.86) between platelet analyzer readings and aggregation was observed. One tablet of aspirin moderately inhibited expression of most surface platelet receptors measured, and such inhibition reached significance (p",
keywords = "Aspirin, Coronary artery disease, Platelet, Receptor",
author = "Malinin, {Alex I.} and Dan Atar and Callahan, {Kevin P.} and McKenzie, {Marcus E.} and Serebruany, {Victor L.}",
year = "2003",
month = "2",
day = "21",
doi = "10.1016/S0014-2999(02)02956-4",
language = "English (US)",
volume = "462",
pages = "139--143",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease

AU - Malinin, Alex I.

AU - Atar, Dan

AU - Callahan, Kevin P.

AU - McKenzie, Marcus E.

AU - Serebruany, Victor L.

PY - 2003/2/21

Y1 - 2003/2/21

N2 - We sought to assess how one tablet of non-enteric coated aspirin (325 mg) affects human platelets in subjects with risk factors for coronary artery disease. Data from 63 individuals with multiple cardiac risk factors were analyzed. Platelets were assessed twice at baseline (pre-aspirin), and after 3-4 h (post-aspirin). We employed 5 μM epinephrine-induced conventional aggregometry, closure time with epinephrine/collagen cartridge by PFA-100® (Dade-Behring), and aspirin response units (ARU) stimulated by propyl gallat with Ultegra® (Accumetrics, San Diego, CA, USA) for measuring platelet function. In addition, the expression of platelet receptors was determined by using the following monoclonal antibodies: anti-CD31, CD41, CD42b, CD51/CD61, CD62p, CD63, CD107a, and CD151. Platelet-leukocyte formation was detected utilizing dual antibodies for a pan-platelet marker CD151, and CD14, a monocyte/macrophage marker. PAC-1 was used to measure fibrinogen-platelet binding. One pill of aspirin significantly decreased platelet-rich plasma (PRP) aggregation (74.18±16.75% vs. 24.92±8.64%; p2=0.73-0.86) between platelet analyzer readings and aggregation was observed. One tablet of aspirin moderately inhibited expression of most surface platelet receptors measured, and such inhibition reached significance (p

AB - We sought to assess how one tablet of non-enteric coated aspirin (325 mg) affects human platelets in subjects with risk factors for coronary artery disease. Data from 63 individuals with multiple cardiac risk factors were analyzed. Platelets were assessed twice at baseline (pre-aspirin), and after 3-4 h (post-aspirin). We employed 5 μM epinephrine-induced conventional aggregometry, closure time with epinephrine/collagen cartridge by PFA-100® (Dade-Behring), and aspirin response units (ARU) stimulated by propyl gallat with Ultegra® (Accumetrics, San Diego, CA, USA) for measuring platelet function. In addition, the expression of platelet receptors was determined by using the following monoclonal antibodies: anti-CD31, CD41, CD42b, CD51/CD61, CD62p, CD63, CD107a, and CD151. Platelet-leukocyte formation was detected utilizing dual antibodies for a pan-platelet marker CD151, and CD14, a monocyte/macrophage marker. PAC-1 was used to measure fibrinogen-platelet binding. One pill of aspirin significantly decreased platelet-rich plasma (PRP) aggregation (74.18±16.75% vs. 24.92±8.64%; p2=0.73-0.86) between platelet analyzer readings and aggregation was observed. One tablet of aspirin moderately inhibited expression of most surface platelet receptors measured, and such inhibition reached significance (p

KW - Aspirin

KW - Coronary artery disease

KW - Platelet

KW - Receptor

UR - http://www.scopus.com/inward/record.url?scp=12244255075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244255075&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(02)02956-4

DO - 10.1016/S0014-2999(02)02956-4

M3 - Article

C2 - 12591106

AN - SCOPUS:12244255075

VL - 462

SP - 139

EP - 143

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -